Orionis Biosciences Announces Collaboration with Genentech to Discover and Develop Molecular Glue Class Medicines

Orionis to receive $47 million upfront, as well as future milestone-related payments. Orionis will leverage its Allo-Glue™ platform for discovery of small molecule monovalent glues. September 20, 2023, BOSTON, MA and GHENT, Belgium – Orionis Biosciences, a privately held life sciences company with an integrated drug discovery and chemical biology platform, announced today a multi-year…